Curated News
By: NewsRamp Editorial Staff
August 10, 2026

NanoViricides Gets Approval for Ebola Trial in DRC

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • NanoViricides gains regulatory approval for Ebola Phase II trial, positioning ahead in outbreak treatment market.
  • NV-387 oral gummies mimic host features to block viral entry, now approved for Phase II trial in DRC.
  • Oral Ebola treatment could save lives in remote areas, simplifying care during deadly outbreaks.
  • Gummy antivirals for Ebola? NanoViricides' chewable NV-387 heads to Congo for testing.

Impact - Why it Matters

This development is significant because it marks a potential breakthrough in the treatment of Ebola, a disease with high mortality and limited therapeutic options. If successful, NV-387 Oral Gummies could provide a more accessible and easier-to-administer treatment compared to intravenous therapies, especially in resource-constrained outbreak regions. The trial's progress could also validate NanoViricides' broad-spectrum antiviral platform, which may have implications for treating other viral diseases like COVID-19 and influenza, potentially impacting global pandemic preparedness and response.

Summary

NanoViricides, Inc. (NYSE American: NNVC) has received regulatory approval from ACOREP in the Democratic Republic of Congo to initiate a Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo ebolavirus outbreak and other Ebola viruses. The company has engaged Om Sai Clinical Research Private Limited as the contract research organization, with initial preparations underway to accelerate first patient dosing. Sufficient quantities of the oral gummies are already in the DRC, positioning the trial for rapid commencement.

NV-387 is an investigational broad-spectrum antiviral designed to mimic host-side features that viruses require for infection, potentially offering advantages in resource-limited settings compared to infusion-based treatments. The company cited WHO data showing 4,141 confirmed cases and 1,889 confirmed deaths from the current outbreak as of Aug. 6, 2026, underscoring the urgent need for effective therapies. The oral formulation could significantly improve patient access and compliance in outbreak zones.

NanoViricides is a clinical-stage company specializing in nanomedicine-based antiviral therapies. Its lead candidate, NV-387, is being developed for multiple viral infections, including RSV, COVID-19, influenza, and Ebola. The company's technology, licensed from TheraCour Pharma, aims to create broad-spectrum antivirals with novel mechanisms. This trial represents a critical step in advancing NV-387 toward potential approval, offering hope for better management of Ebola outbreaks and other viral threats. For more details, visit https://ibn.fm/2Pqu0.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Gets Approval for Ebola Trial in DRC

blockchain registration record for this content.